Patents by Inventor Megan MCKENNEY

Megan MCKENNEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds useful for inhibiting RET kinase
    Patent number: 11964968
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: April 23, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Erin D. Anderson, Steven W. Andrews, Kevin R. Condroski, Thomas C. Irvin, Gabrielle R. Kolakowski, Manoj Kumar, Elizabeth A. McFaddin, Megan McKenney, Michael J. Munchhof, Michael B. Welch
  • COMPOUNDS USEFUL FOR INHIBITING RET KINASE
    Publication number: 20230312544
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Application
    Filed: February 6, 2023
    Publication date: October 5, 2023
    Inventors: Erin D. ANDERSON, Steven W. ANDREWS, Kevin R. CONDROSKI, Thomas C. IRVIN, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan MCKENNEY, Michael J. MUNCHHOF, Michael B. WELCH
  • Compounds useful for inhibiting RET kinase
    Patent number: 11613533
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: March 28, 2023
    Assignee: Eli Lilly and Company
    Inventors: Erin D. Anderson, Steven W. Andrews, Kevin R. Condroski, Thomas C. Irvin, Gabrielle R. Kolakowski, Manoj Kumar, Elizabeth A. McFaddin, Megan McKenney, Michael J. Munchhof, Michael B. Welch
  • COMPOUNDS USEFUL FOR INHIBITING RET KINASE
    Publication number: 20210363140
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Application
    Filed: April 23, 2021
    Publication date: November 25, 2021
    Inventors: Erin D. ANDERSON, Steven W. ANDREWS, Kevin R. CONDROSKI, Thomas C. IRVIN, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan MCKENNEY, Michael J. MUNCHHOF, Michael B. WELCH